Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB3 | P54753 | 2/20 | 0.63 |
| ▸ | KMO | O15229 | 1/20 | 0.48 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | PRKDC | P78527 | 2/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.42 |
| ▸ | BAZ2B | Q9UIF8 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17454455 | 0.88 | EPHB3 (0.62) | EPHB3KMOALDH1A1PRKDCBRD9 | |
| SCHEMBL27431439 | 0.88 | EPHB3 (0.62) | EPHB3KMOPRKDCBRD9BAZ2B | |
| SCHEMBL15039556 | 0.88 | EPHB3 (0.60) | EPHB3ALDH1A1L3MBTL1KDM4EMEN1 | |
| SCHEMBL17452618 | 0.85 | EPHB3 (0.59) | EPHB3KMOALDH1A1PRKDCBRD9 | |
| SCHEMBL31469893 | 0.82 | EPHB3 (0.56) | EPHB3PKMALDH1A1SMN1; SMN2PIK3CA | |
| SCHEMBL24567287 | 0.81 | EPHB3 (0.53) | EPHB3KMOPKMALDH1A1SMN1; SMN2 | |
| SCHEMBL17437981 | 0.80 | ROCK2 (0.47) | EPHB3KMOSLC16A3PKMALDH1A1 | |
| SCHEMBL2875489 | 0.78 | EPHB3 (1.00) | EPHB3KDM4EKMT2A | |
| SCHEMBL20220366 | 0.78 | EPHB3 (0.59) | EPHB3PKMALDH1A1SMN1; SMN2PIK3CA | |
| SCHEMBL33913 | 0.78 | SMPD3 (0.55) | EPHB3ALDH1A1SMN1; SMN2PRKDCPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049080-A1 | WILD TYPE KIT INHIBITORS | BLUEPRINT MEDICINES CORP (US) | 2026-02-19 | — | — | US | disclosed |
| US-12448379-B2 | Wild type kit inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250051363-A1 | Substituted Pyrazolopyridines | NEURO3 THERAPEUTICS INC (US) | 2025-02-13 | — | — | US | disclosed |
| WO-2025029897-A1 | SUBSTITUTED PYRAZOLOPYRIDINES | NEURO3 THERAPEUTICS, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| US-20240262826-A1 | WILD TYPE KIT INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-08-08 | — | — | US | disclosed |
| WO-2024118887-A1 | N-PHENYL-PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS WILD TYPE C-KIT KINASE INHIBITORS FOR THE TREATMENT OF URTICARIA | BLUEPRINT MEDICINES CORPORATION (US) | 2024-06-06 | — | — | WO | disclosed |
| CN-106817899-B | Spiroheptane as ROCK inhibitor | 百时美施贵宝公司 | 2021-03-09 | — | — | CN | disclosed |
| EP-3169682-B1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-12-26 | — | — | EP | disclosed |
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
| US-20160016914-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-21 | — | — | US | disclosed |
| US-20160016914-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-21 | — | — | US | disclosed |
| US-20160016914-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-21 | — | — | US | disclosed |
| WO-2016010950-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051363-A1 | Substituted Pyrazolopyridines | QDPR, DPYD, P2RX4 | EPHB3 2310/4885KMO 3512/4885SLC16A3 3305/4885 |
| US-20260049080-A1 | WILD TYPE KIT INHIBITORS | KIT, CSNK1A1, CSNK1A1L | EPHB3 2198/4885KMO 1447/4885SLC16A3 1252/4885 |
| US-12448379-B2 | Wild type kit inhibitors | KIT, TNK1, TNNI3K | EPHB3 2426/4885KMO 3143/4885SLC16A3 1484/4885 |
| US-20240262826-A1 | WILD TYPE KIT INHIBITORS | KIT, TNK1, TNNI3K | EPHB3 2426/4885KMO 3143/4885SLC16A3 1484/4885 |
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | EPHB3 1833/4885KMO 953/4885SLC16A3 3798/4885 |
| US-20160016914-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | EPHB3 1833/4885KMO 953/4885SLC16A3 3798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.